Harbour Capital Advisors, LLC
Position in TRVI — Trevi Therapeutics, Inc.
CIK 1682501
TYSONS CORNER, VA
Position in TRVI
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$749,730
+$264,179 QoQ
Shares Held
40,200
-1.2% QoQ
Ownership
0.028%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#6
of 25 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TRVI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Harbour Capital Advisors, LLC holds $5,783,688 across 7 Biotechnology names. TRVI ranks #2 (13.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,051 | $3,005,713 | |
| 2 | TRVI |
Trevi Therapeutics, Inc.
This page
|
40,200 | $749,730 | |
| 3 | EXEL |
Exelixis, Inc.
|
9,005 | $489,962 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
12,170 | $474,751 | |
| 5 | SNDX |
Syndax Pharmaceuticals Inc
|
20,650 | $451,409 | |
| 6 | KLRA |
Kailera Therapeutics, Inc.
|
16,570 | $365,037 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
7,400 | $247,086 |
All Filings in TRVI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $749,730 | 40,200 | Shares | Sole | 2026-07-15 | |
| 2026-03-31 | $485,551 | 40,700 | Shares | Sole | 2026-04-29 | |
| 2025-12-31 | $344,300 | 27,500 | Shares | Sole | 2026-01-07 | |
| 2025-09-30 | $251,625 | 27,500 | Shares | Sole | 2025-10-09 | |
| No filing history on record for this holder in this stock. | ||||||